AI and GLP-1 drugs: Eli Lilly & Co.’s CEO talks of focus beyond 150 years
AI and GLP-1 drugs: Eli Lilly & Co.’s CEO talks of focus beyond 150 years
Publish Date: 2026-05-12 18:55:00
Source Domain: www.wrtv.com
- Eli Lilly & Co. is heavily investing in artificial intelligence (AI) to expedite drug research and possibly automate unsafe or repetitive manufacturing processes.
- The company is celebrating its 150th anniversary, with the event emceed by Peyton Manning and attended by key state leaders.
- Ricks mentioned the company’s active progress in the early stages of developing GLP-1 weight-loss drugs, along with multiple follow-up medications to address side effects.
- Lilly is also developing stronger drugs to assist those who are severely overweight, showing a commitment to diverse weight-loss solutions.
- The company is pushing forward in research for neurodegenerative diseases, emphasizing their desire to innovate in areas like Alzheimer’s, Parkinson’s, and ALS.
- Ricks underscored AI’s role in drug design and research, highlighting Lilly’s acquisition of the industry’s most powerful supercomputer for these efforts.
